Centus Gets European Bevacizumab Approval
Equidacent Rival To Avastin Gains Marketing Authorization
Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.
You may also be interested in...
With the European Commission’s approval of Aybintio (bevacizumab), Samsung Bioepis now has five approved biosimilars for Europe.
Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.
The market for biosimilar Avastin is set to form imminently, with two players holding final approvals from the European Commission waiting in the wings. In the coming days, the EMA’s Committee for Medicinal Products for Human Use is likely to issue an opinion on a further application.